Thanks to the development of effective oncology therapies, the survival rate of pediatric oncology patients is greater than ever before. Widely used as first-line and second-line treatments for various oncological diseases, chemotherapy and radiation therapy also have negative effects on healthy cells, which can lead to many side effects, including endocrine and metabolic disorders. Risk factors for adrenal disease include chemotherapy and other drugs used in oncology, including glucocorticosteroids (GCS) affecting the hypothalamic-pituitary-adrenal axis (HPAA), as well as radiotherapy to the head, neck and abdomen, which may temporarily or permanently interfere with the proper functioning of the adrenal glands. Secondary adrenal insufficiency may develop after abrupt discontinuation of GCS and after radiotherapy of the head area, especially at a dose above 30 Gy. Therefore, it was necessary to evaluate the adrenal function in people with a history of cancer. In this work, we focused on screening and early detection of AI before the onset of symptoms of this disease, which minimizes the risk of adrenal crisis and improves the quality of life of patients after oncological treatment. Based on our data, monitoring of adrenal function is important in ALL survivors and neuroblastomas, while for other cancers the problem is less likely. However, our research did ; not include patients after treatment of brain tumors who are known to be at risk of HPAA dysfunction, and this issue will be the subject of our further research.
endokrynologia ; onkologia ; pediatria
Rada Dyscypliny Nauki medyczne
15 maj 2024
24 lis 2023
6
0
http://dl.cm-uj.krakow.pl:8080/publication/5000
Nazwa wydania | Data |
---|---|
ZB-136937 | 15 maj 2024 |
Hull, Barbara
Olszewska, Marta
Słupińska, Monika
Rozwadowski, Maciej
Marć, Małgorzata Anna
Rosa, Jozef